Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer
研究概览
简要总结
A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.
详细描述
Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from thyroid C cells. Neuroendocrine tumors have been demonstrated to express somatostatin receptors as well as mTOR pathway. The somatostatin analogues now available (octreotide and lanreotide) act preferentially through the somatostatin receptor subtype 2 (sst2). In MTC, these compounds have been reported to exert anti-secretive effects on calcitonin but no anti-proliferative effects.SOM230 (pasireotide) is a new somatostatin analogue showing a peculiar binding profile with high affinity for sst1, sst2, sst3, sst5. Preliminary data show SOM230 to be effective in a phase II study on patients with metastatic carcinoid. RAD001 (everolimus) is a novel agent that interacts with mTOR. It was demonstrated to inhibit tumor growth in neuroendocrine tumor cell lines. Some clinical trials have explored the efficacy of a combined therapy with RAD001 plus octreotide in patients with digestive neuroendocrine tumors, highlighting encouraging results in term of tumor control.In particular, octreotide and RAD001 seem to show a synergistic activity in inhibiting neuroendocrine tumor proliferation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with progressive metastatic or postoperative persistent medullary thyroid cancer who have histopathologically confirmed disease and measurable tumor lesions. (Postoperative persistent after surgical removal is characterized by increased levels of calcitonin with or without radiological detectable tumour relapse or metastases.)
- •Patients with evidence of biochemical progression of disease, as expressed by progressive increase of serum calcitonin levels, assessed once a month for at least three months before study entry, according to RECIST definitions (elevation of the markers for at least 25 %).
- •Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
- •Adequate organ function - Karnofsky-Index performance status >60%
- •Life expectancy > 6 months
- •Age > 18 years
- •Women of childbearing potential must have a negative serum pregnancy test within 14 days of randomization and a urine pregnancy test 48 hours prior to the administration of the first study treatment.
- •Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary.
- •Signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial prior to enrolment.
排除标准
- •Unstable systemic diseases including uncontrolled hypertension, active uncontrolled infections, psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
- •Known hypersensitivity to somatostatin analogues.
- •Pregnant or breast-feeding patients
- •Sign of recurrence of prior or concomitant malignancies (within the last 3 years or requiring active treatment) other than MTC; with the exception of previous basal cell skin cancer, previous cervical carcinoma in situ
- •Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus)
- •Participation in a clinical trial to test an investigational drug within 4 weeks prior to visit
- •Any of severe and/or uncontrolled medical conditions:
- •Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment,
- •QT related exclusion criteria
- •Previous treatments with chemotherapy, loco regional therapy (eg, chemoembolization) or interferon are permitted providing that toxicity has resolved to < Grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment.
研究组 & 干预措施
SOM230 alone or in combination with RAD001
Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
干预措施: SOM230 alone or in combination with RAD001. (Drug)
结局指标
主要结局
Efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer
时间窗: From date of start therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
Efficacy is defined as progression-free survival (PFS), according to RECIST criteria, in patients treated with SOM230.
次要结局
- Time to response(From date of start therapy, 3 month, 6 month time point evaluation, up to 6 months.)
- Biochemical response(From date of start therapy, 1 month, 2 month, 3 month, 6 month time point evaluation, up to 6 months.)
- Objective tumor response(From date of start therapy, 3 month, 6 month time point evaluation, up to 6 months.)
- Overall survival(From date of start therapy to the end of the study or death from any cause, whichever came first, up to 6 months.)
- Efficacy of SOM230 in combination with RAD001 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.(From date of start therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.)
- Duration of response(From time of response to time of tumor progression or death from any cause, whichever came first.)
- Safety(From date of start therapy until the end of the study, every 30 days, up to 6 months.)
研究者
Annamaria Colao
Professor
Federico II University